25 Feb 2014 11:38
Omega Diagnostics Group PLC
("Omega" or the "Company")
Grant of Options
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that its Remuneration Committee on 25 February 2014 awarded the following director share options:
Options granted 25 February 2014 | Total options following grant | |||
Andrew Shepherd | 800,000 | 2,103,480 | ||
Kieron Harbinson | 640,000 | 1,408,987 | ||
Jag Grewal | 610,000 | 910,000 |
All options are awarded under the Company's EMI Share Option Scheme. The options have a three year vesting period, have been awarded at an exercise price of 30.5p (closing mid-market price on 24 February 2014) and after they are fully vested, there is a performance criteria that they cannot be exercised until the share price is at 50p or higher.
Contacts:
Omega Diagnostics Group PLC | Tel: 01259 763 030 |
Andrew Shepherd, Chief Executive | www.omegadiagnostics.com |
Kieron Harbinson, Group Finance Director | |
Jag Grewal, Group Sales and Marketing Director | |
finnCap Ltd | Tel: 020 7220 0500 |
Geoff Nash/Christopher Raggett (Corporate Finance) | |
Stephen Norcross/Mia Gardner (Corporate Broking) | |
Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
ODX.L (ODX)